Actinic Keratosis Clinical Trial
Official title:
Study on the Efficacy of LAS41005 Compared to Placebo and to LAS106521 in the Treatment of Actinic Keratosis Grade I to II
Verified date | July 2015 |
Source | Almirall, S.A. |
Contact | n/a |
Is FDA regulated | No |
Health authority | Germany: Federal Institute for Drugs and Medical Devices |
Study type | Interventional |
The purpose of this study is to investigate the efficacy of LAS41005 in comparison to placebo and to LAS106521 in actinic keratosis (AK).
Status | Completed |
Enrollment | 470 |
Est. completion date | June 2009 |
Est. primary completion date | June 2009 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years to 85 Years |
Eligibility |
Main Inclusion Criteria: - Have at least 4 but not more than 10 clinically confirmed AK target lesions of mild to moderate intensity within the face/forehead or bald scalp (excluding eyelids, lips, and mucosa), i.e. actinic keratosis grade I and II according to Olsen EA et al. 1991 - Woman of childbearing potential are allowed to participate in this study only if they use a highly effective method of contraception Main Exclusion Criteria: - Have received effective treatment of AK in the three months preceding this clinical trial - Have known hypersensitivity to LAS41005 or LAS106521 - Have currently other malignant or benign tumors of the skin within the treatment area (e.g. malignant melanoma, basal cell carcinoma, squamous cell carcinoma) - Patient's taking phenytoin - Show cornu cutaneum like alterations of the skin in the face or the bald scalp (target area) |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Germany | Almirall Facility Site#37 | Altenkirchen | |
Germany | Almirall Facility Site#23 | Augsburg | |
Germany | Almirall Facility Site#24 | Augsburg | |
Germany | Almirall Facility Site#01 | Berlin | |
Germany | Almirall Facility Site#02 | Berlin | |
Germany | Almirall Facility Site#28 | Berlin | |
Germany | Almirall Facility Site#34 | Berlin | |
Germany | Almirall Facility Site#35 | Berlin | |
Germany | Almirall Facility Site#31 | Bonn | |
Germany | Almirall Facility Site#04 | Buxtehude | |
Germany | Almirall Facility Site#40 | Detmold | |
Germany | Almirall Facility Site#30 | Dresden | |
Germany | Almirall Facility Site#11 | Dülmen | |
Germany | Almirall Facility Site#12 | Düsseldorf | |
Germany | Almirall Facility Site#17 | Frankfurt | |
Germany | Almirall Facility Site#22 | Freiburg | |
Germany | Almirall Facility Site#36 | Friedrichshafen | |
Germany | Almirall Facility Site#19 | Fulda | |
Germany | Almirall Facility Site#32 | Göttingen | |
Germany | Almirall Facility Site#09 | Hamburg | |
Germany | Almirall Facility Site#29 | Jena | |
Germany | Almirall Facility Site#07 | Kiel | |
Germany | Almirall Facility Site#08 | Kiel | |
Germany | Almirall Facility Site#15 | Koblenz | |
Germany | Almirall Facility Site#21 | Landau | |
Germany | Almirall Facility Site#27 | Leipzig | |
Germany | Almirall Facility Site#06 | Lübeck | |
Germany | Almirall Facility Site#03 | Mahlow | |
Germany | Almirall Facility Site#25 | München | |
Germany | Almirall Facility Site#39 | München | |
Germany | Almirall Facility Site#33 | Nördlingen | |
Germany | Almirall Facility Site#38 | Osnabrück | |
Germany | Almirall Facility Site#05 | Pinneberg | |
Germany | Almirall Facility Site#26 | Quedlinburg | |
Germany | Almirall Facility Site#20 | Radolfzell | |
Germany | Almirall Facility Site#10 | Salzwedel | |
Germany | Almirall Facility Site#16 | Soest | |
Germany | Almirall Facility Site#14 | Vechta | |
Germany | Almirall Facility Site#18 | Wiesbaden | |
Germany | Almirall Facility Site#13 | Wuppertal |
Lead Sponsor | Collaborator |
---|---|
Almirall, S.A. |
Germany,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Histological status of AK target lesion | Day 140 | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03013647 -
Daylight Photodynamic Therapy for Actinic Keratosis and Skin Field Cancerization
|
N/A | |
Completed |
NCT02674048 -
Metvix Daylight PDT in Actinic Keratosis
|
||
Completed |
NCT02239679 -
Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy
|
Phase 2 | |
Completed |
NCT02421471 -
PMS to Evaluate the Safety and Efficacy of Picato® Gel
|
||
Completed |
NCT01686152 -
Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis
|
Phase 3 | |
Terminated |
NCT01525329 -
Combination Therapy With 5-Fluorouracil and Photodynamic Therapy in Post-transplant Premalignant Skin Disease
|
Phase 3 | |
Completed |
NCT01444989 -
Development and Validation of a Quality of Life Instrument for Actinic Keratosis
|
N/A | |
Completed |
NCT01449513 -
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
|
Phase 1 | |
Terminated |
NCT01203878 -
Treatment of Actinic Keratoses of the Face With Imiquimod 3.75% Cream Followed by Photodynamic Therapy
|
Phase 4 | |
Completed |
NCT00989313 -
A Long Term Follow up Study of Patients Who Have Complete Clearance of Their Actinic Keratosis (AK) Lesions at the Day 57 Visit in the PEP005-028 Study
|
Phase 3 | |
Completed |
NCT00306800 -
Metvix PDT Versus Vehicle PDT With Aktilite CL128 Lamp in Patients With Actinic Keratosis on the Face and Scalp
|
Phase 3 | |
Completed |
NCT00375739 -
Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses
|
Phase 2 | |
Completed |
NCT03285490 -
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on Actinic Keratosis on Face or Scalp (AK004)
|
Phase 3 | |
Completed |
NCT03319251 -
Biomarker Database Registry for Photodynamic Therapy
|
||
Completed |
NCT02866695 -
Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients
|
Phase 4 | |
Completed |
NCT02952898 -
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
|
Phase 3 | |
Completed |
NCT02984072 -
Menthol for PDT Pain Relief
|
Phase 4 | |
Recruiting |
NCT03684772 -
Topical Ionic Contra-Viral Therapy in Actinic Keratosis
|
Phase 2 | |
Completed |
NCT02902822 -
Tele-dermatology of Skin Cancer in a Cohort of Local Health Authority Employees in the Province of Bergamo
|
N/A | |
Completed |
NCT02878382 -
Potential Impact of Patient Vitamin D Status in AK Response to MAL-PDT
|
N/A |